Abbott (NYSE: ABT) EVP granted stock options and performance shares

Rhea-AI Filing Summary

Cushman Elizabeth C. reported acquisition or exercise transactions in this Form 4 filing.

Abbott Laboratories executive Elizabeth C. Cushman, EVP, GC and Secretary, reported equity awards on February 24, 2026. She received an employee stock option for 61,964 options under the Abbott 2017 Incentive Stock Program, exercisable in three annual installments starting in 2027. She was also granted 15,031 performance-based restricted shares with a three-year term, with no more than one-third vesting in any year, contingent on Abbott reaching a minimum return-on-equity target and allowing shares to be withheld for taxes.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Cushman Elizabeth C.

Role EVP, GC AND SECRETARY

Type	Security	Shares	Price	Value
Grant/Award	Option (right to buy)	61,964	$0.00	--
Grant/Award	Common shares without par value	15,031	$0.00	--

Holdings After Transaction: Option (right to buy) — 61,964 shares (Direct); Common shares without par value — 40,257 shares (Direct)

Footnotes (1)

1. These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 20,654 on February 24, 2027, 20,655 on February 24, 2028, and 20,655 on February 24, 2029.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cushman Elizabeth C.

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, GC AND SECRETARY

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares without par value	02/24/2026		A		15,031(1)	A	$0	40,257	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)(2)	$114.6	02/24/2026		A		61,964		02/24/2027	02/23/2036	Common Shares	61,964	$0	61,964	D

Explanation of Responses:

1. These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

2. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 20,654 on February 24, 2027, 20,655 on February 24, 2028, and 20,655 on February 24, 2029.

	/s/ Elizabeth C. Cushman, by Jessica H. Paik, Attorney-in-Fact	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Abbott (ABT) executive Elizabeth C. Cushman receive?

Elizabeth C. Cushman received 61,964 stock options and 15,031 performance-based restricted shares under Abbott’s 2017 Incentive Stock Program. The options and shares vest over multiple years, subject to specific schedule and performance conditions described in the awards.

How do Elizabeth C. Cushman’s new Abbott (ABT) stock options vest?

Cushman’s 61,964 employee stock options vest in three annual increments. They become exercisable for 20,654 options on February 24, 2027, and for 20,655 options on both February 24, 2028, and February 24, 2029, under Abbott’s 2017 Incentive Stock Program.

What are the performance conditions on Abbott (ABT) restricted stock granted to Elizabeth C. Cushman?

The 15,031 restricted shares are performance-based with a three-year term. No more than one-third can vest in any year, and vesting requires Abbott to reach a minimum return-on-equity target, directly linking Cushman’s award value to the company’s profitability performance.

Are taxes addressed in Elizabeth C. Cushman’s Abbott (ABT) restricted stock award?

Yes. The performance-based restricted stock award includes a feature allowing shares to be withheld for tax purposes. This means Abbott can retain a portion of vested shares to cover applicable taxes instead of Cushman paying cash separately.

Under what program were Elizabeth C. Cushman’s Abbott (ABT) equity awards granted?

Both the stock options and performance-based restricted shares were granted under the Abbott Laboratories 2017 Incentive Stock Program. The Form 4 notes the employee stock option grant occurred in a transaction exempt from Section 16 under Rule 16b-3.

What type of Form 4 transactions did Abbott (ABT) report for Elizabeth C. Cushman?

The Form 4 reports two acquisition-type transactions coded “A.” One is a grant of 61,964 stock options, and the other is a grant of 15,031 performance-based restricted shares, both treated as grant or award acquisitions rather than open-market purchases.